Boston Scientific Co. (NYSE:BSX) EVP Arthur C. Butcher Sells 17,313 Shares of Stock

Boston Scientific Co. (NYSE:BSX) EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Boston Scientific Stock Performance

BSX stock opened at $103.53 on Wednesday. The stock’s fifty day moving average is $93.75 and its two-hundred day moving average is $86.53. The stock has a market capitalization of $152.58 billion, a price-to-earnings ratio of 85.56, a PEG ratio of 2.68 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 1 year low of $64.08 and a 1 year high of $104.25.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BSX. Royal Bank of Canada raised their target price on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Stifel Nicolaus lifted their price objective on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 18th. TD Cowen increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Truist Financial lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Sanford C. Bernstein increased their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $100.39.

Institutional Trading of Boston Scientific

Several hedge funds have recently bought and sold shares of BSX. Quarry LP bought a new position in shares of Boston Scientific in the second quarter worth $33,000. Czech National Bank lifted its holdings in Boston Scientific by 7.1% in the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock worth $25,139,000 after purchasing an additional 19,833 shares during the period. GAMMA Investing LLC grew its position in Boston Scientific by 39.9% in the 3rd quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after buying an additional 4,972 shares in the last quarter. Miracle Mile Advisors LLC increased its stake in Boston Scientific by 4.0% during the 3rd quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock valued at $440,000 after buying an additional 203 shares during the period. Finally, Bank of New Hampshire raised its position in shares of Boston Scientific by 52.6% during the 3rd quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock worth $187,000 after buying an additional 770 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.